Senores Pharmaceuticals Limited has informed the Exchange regarding the media release in relation to the Audited Consolidated and Standalone financial results of the Company for quarter ....
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals reported exceptional Q4 and FY26 results with Total Income of Rs. 190 Cr for Q4 (+66% YoY) and Rs. 664 Cr for FY26 (+65% YoY). EBITDA surged to Rs. 62 Cr in Q4 (+219%) and Rs. 200 Cr for FY26 (+114%), while PAT grew to Rs. 37 Cr in Q4 (+104%) and Rs. 122 Cr for FY26 (+108%). Regulated Markets drove most growth with revenue of Rs. 427 Cr in FY26 (+91%), while Branded Generics saw 385% YoY growth to Rs. 40 Cr. The company expanded through Apnar Pharmaceuticals acquisition (75% stake) and launched a 70% JV Amerisyn for U.S. federal market access. Cash flow from operations stood at Rs. 75 Crs. The ANDA portfolio now has 51 approved products (151 strengths) with 30 awaiting commercialization and 27 more in development.
Strong double-digit growth across all metrics with improving profitability margins indicates operational leverage is working. New acquisitions (Apnar, Zoraya) and the Amerisyn JV expand market reach in the high-margin U.S. regulated market. The robust ANDA pipeline provides multi-year growth visibility.